OOIR: Observatory of International Research

Papers

(The H4-Index of Drug Safety is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Correction to: Review of Over 15 Years Postmarketing Safety Surveillance Spontaneous Data for the Human Rotavirus Vaccine (Rotarix) on Intussusception	148
Post-Marketing Safety Profile of Vortioxetine Using a Cluster Analysis and a Disproportionality Analysis of Global Adverse Event Reports	102
Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative	96
Impact of Batoclimab Treatment on LDL-C with and Without Coadministration of Atorvastatin: Results from a Phase I Randomized Study in Healthy Participants	86
Algorithms to Identify Major Congenital Malformations in Routinely Collected Healthcare Data: A Systematic Review	76
Comment on “Performance and Reproducibility of Large Language Models in Named Entity Recognition: Considerations for the Use in Controlled Environments”	76
Potential Risk Factors of Drug-Related Problems in Hospital-Based Mental Health Units: A Systematic Review	62
Validation of a Natural Language Machine Learning Model for Safety Literature Surveillance	55
Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System	46
Acknowledgement to Referees	44
Authors’ Reply to Mungmunpuntipantip et al.’s Comment on “Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands”	44
High-Dimensional Propensity Score-Adjusted Case-Crossover for Discovering Adverse Drug Reactions from Computerized Administrative Healthcare Databases	42
Emergency Department Use of Heart Failure-Exacerbating Medications in Patients with Chronic Heart Failure	41
A Comparison of Active Pharmacovigilance Strategies Used to Monitor Adverse Events to Antiviral Agents: A Systematic Review	40
Meeting Report: Herbal and Dietary Supplement Safety Surveillance Summit	39
Comparison of the MOdified NARanjo Causality Scale (MONARCSi) for Individual Case Safety Reports vs. a Reference Standard	39
Early Detection of Hearing Impairment Signals Post-mRNA COVID-19 Vaccination: A Disproportionality Analysis Study on French Pharmacovigilance Database	37
Use of Electrocardiogram Monitoring in Adult Patients Taking High-Risk QT Interval Prolonging Medicines in Clinical Practice: Systematic Review and Meta-analysis	36
21st ISoP Annual Meeting “A New Era of Pharmacovigilance: Challenges and Opportunities” 20–23 September 2022 Verona, Italy	33
An Integrated Approach for Representing Knowledge on the Potential of Drugs to Cause Acute Kidney Injury	32
Incretin-Based Drugs and the Risk of Dementia Among Patients with Type 2 Diabetes	32
Sex Differences in Electrolyte Disturbances Among Diuretic Users According to Renal Function and Age	31
Uncovering the Hidden Hurdles: Exploring Challenges in Pediatric Pharmacovigilance in the Netherlands	31
Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database	27
Comment on "Drug–Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data"	26

Pharmacovigilance in Cell and Gene Therapy: Evolving Challenges in Risk Management and Long-Term Follow-Up	25
Correction to: Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission Networks	25
A Disproportionality Analysis of Drug–Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)	25
Preventable Deaths Involving Medicines: A Systematic Case Series of Coroners’ Reports 2013–22	25
Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study	25
The Rationale for Robust Pharmacovigilance in Monitoring the Safety of Traditional Medicines and Natural Health Products	25